We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+33.35%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$2.6B
AUM Growth
+$504M
Cap. Flow
+$116M
Cap. Flow %
4.45%
Top 10 Hldgs %
62.82%
Holding
68
New
12
Increased
10
Reduced
11
Closed
26

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$90.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$86M
3
PTCT icon
PTC Therapeutics
PTCT
+$71.6M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$69.4M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$63.4M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$83.4M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$48.5M
3
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$45.2M
4
DVAX
Dynavax Technologies
DVAX
+$32.8M
5
ARRY
Array Biopharma Inc
ARRY
+$31.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
26
DELISTED
Teligent, Inc
TLGT
$18.3M 0.71%
529,943
– –
CBAY
27
DELISTED
Cymabay Therapeutics
CBAY
$17.2M 0.66%
+1,282,374
New +$16M
DERM
28
DELISTED
Dermira, Inc.
DERM
$16.9M 0.65%
1,841,823
-1,585,555
-46% -$14.8M
BDSI
29
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$16M 0.62%
5,437,779
– –
CPRX
30
DELISTED
Catalyst Pharmaceutical
CPRX
$14M 0.54%
4,497,042
-195,301
-4% -$593K
CARM
31
DELISTED
Carisma Therapeutics
CARM
$13.3M 0.51%
+340,000
New +$15M
INDP icon
32
Indaptus Therapeutics
INDP
$468M
$11.3M 0.44%
1,148
+168
+17% +$1.86M
XENE icon
33
Xenon Pharmaceuticals
XENE
$5.49B
$11.1M 0.43%
+1,202,118
New +$7.47M
FENC icon
34
Fennec Pharmaceuticals
FENC
$362M
$10.7M 0.41%
1,022,666
+750,000
+275% +$8.89M
ARWR icon
35
Arrowhead Research
ARWR
$10.3B
$6.12M 0.24%
+450,000
New +$4.21M
ALIM
36
DELISTED
Alimera Sciences
ALIM
$6.11M 0.24%
416,105
– –
ONCS
37
DELISTED
OncoSec Medical Incorporated
ONCS
$5.53M 0.21%
18,217
– –
XBI icon
38
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$5.3M 0.2%
1,750,000
+1,000,000
+133% +$91.9M
TECX
39
Tectonic Therapeutic
TECX
$550M
$2.86M 0.11%
+8,333
New +$3.01M
OTLK icon
40
Outlook Therapeutics
OTLK
$156M
$578K 0.02%
4,272
– –
ONSIW
41
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$12K ﹤0.01%
233,333
– –
ACAD icon
42
CALL
Acadia Pharmaceuticals
ACAD
$4.62B
– –
-500,000
Closed -$363K
ACAD icon
43
Acadia Pharmaceuticals
ACAD
$4.62B
– –
-317,100
Closed -$7.13M
AGEN
44
Agenus
AGEN
$315M
– –
-35,897
Closed -$3.32M
APLS
45
DELISTED
Apellis Pharmaceuticals
APLS
– –
-396,635
Closed -$7.45M
AZN icon
46
AstraZeneca
AZN
$253B
– –
-375,150
Closed -$26.2M
BMRN icon
47
CALL
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-162,500
Closed -$214K
DVAX
48
DELISTED
Dynavax Technologies
DVAX
– –
-1,650,700
Closed -$32.8M
FOLD
49
CALL
DELISTED
Amicus Therapeutics
FOLD
– –
-2,350,100
Closed -$3.76M
GYRE icon
50
Gyre Therapeutics
GYRE
$696M
– –
-136,550
Closed -$26.4M
1
2
3

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q2 2018 Portfolio in Review

As of Q2 2018, Avoro Capital Advisors held 68 positions worth $2.6B, up 24% from $2.09B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Avoro Capital Advisors deployed $116M of net new capital in Q2 2018, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Sarepta Therapeutics: 958,928 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $48.5M trimmed.

  • Avoro Capital Advisors's largest Q2 2018 buy was Sarepta Therapeutics: 958,928 shares worth $127M.
  • Avoro Capital Advisors added most to Immunomedics Inc in Q2 2018, an estimated $15.6M increase.
  • Avoro Capital Advisors's biggest Q2 2018 reduction was Global Blood Therapeutics, Inc., cutting an estimated $48.5M.
  • Avoro Capital Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $83.4M.
  • Avoro Capital Advisors's ten largest holdings make up 63% of its $2.6B portfolio in Q2 2018.
  • Avoro Capital Advisors opened 12 new positions and closed 26 in Q2 2018.
  • Avoro Capital Advisors's portfolio value rose 24% quarter-over-quarter to $2.6B.

Based on Avoro Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.